transporters for organic cations and glycemic control in patients with neuropathic pain.

Conditions: Neuropathic Pain; Type 2 Diabetes Mellitus; Diabetic Neuropathy, Painful

Summary: this study aimed to investigate the influence of the glycemic control of type 2 diabetes (dm2) and of cetirizine (octs inhibitor) on gabapentin kinetics disposition and pharmacodynamics (pk-pd) in patients with neuropathic pain. thus, non-diabetic patients (control group, n=10), patients with controlled diabetes (n=9) and patients with uncontrolled diabetes (n=10), all with neuropathic pain of intensity ≥ 4 in pain visual analog scale (0-10) were investigated.

gabapentin (gbp), anticonvulsant used to neuropathic pain treatment, is mainly eliminated unchanged in urine. renal active tubular secretion has been suggested to contribute on gbp excretion by renal excretion. studies performed on rats with experimental diabetes suggest that hyperglycemia reduces the activity of organic cation transporters (oct). thus, the aim of the study was to investigate the role of octs on kinetic disposition and pharmacodynamics of gbp in patients with neuropathic pain and to verify the regulation of these transporters' activity by glycemic control in diabetes. a cross-over clinical study was performed in patients with neuropathic pain (n=10, control) to evaluate the influence of ctz on gbp kinetic disposition. to evaluate the effect of glycemic control, patients with controlled dm2 (dc, n=9) and uncontrolled dm2 (dnc, n=10) were investigated. all participants investigated had neuropathic pain of intensity ≥ 4 evaluated by analogue visual scale (eva) and were treated with oral single-dose of 300 mg of gbp (phase 1) or cetirizine (20 mg/day) for 5 days and single-dose of gbp on the last day (phase 2). only participants of control group participated of phase 2. serial blood and urine samples were collected up to 36 hours after gbp administration. the intensity of pain was evaluated at the same time of blood sampling, using the visual analog scale. gbp concentration in plasma and urine was validated by jplc-uv. all participants were genotyped for polymorphisms slc22a2 808g\>t and slc22a4 1507c\>t. the pharmacokinetic parameters were estimated by non-compartmental analysis.

Eligibility criteria:
inclusion criteria: * adult patients, both gender * patients with neuropathic pain with score ≥ 4 in visual analog scale * patients with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy with score ≥ 4 in visual analog scale * patients with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy with score ≥ 4 in visual analog scale * patients that suspend the use of analgesics for 10 times half-life before starting the protocol exclusion criteria: * patients with acute or chronicle severe renal failure (creatinine clearance ≤ 30 ml/min) * patients with gastrointestinal diseases * patients with history of alcohol and drug abuse * patients with acute myocardial insufficiency * patients with another kind of chronicle pain as severe as neuropathic pain * patients in chronicle use of drugs that interact with gabapentin (antacids and cimetidine)